dacarbazine has been researched along with Myelodysplastic Syndromes in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, I; Eichenauer, DA; Engert, A; Franklin, J; Monsef, I | 1 |
| Akiyama, M; Matsumoto, T; Nin-Asai, R; Saito, S; Sawada, M; Yokota, K | 1 |
| Brandwein, JM; Galarneau, A; Hogge, D; Howson-Jan, K; Kassis, J; Leber, B; Minden, MD; Pouliot, JF | 1 |
| Rashidi, A; Sorscher, SM | 1 |
| Kesavan, M; Turner, JH | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S | 1 |
| Auger, N; Bhangoo, R; Da Costa, L; Dufour, C; Grill, J; Jullien, M | 1 |
| Chamberlain, MC; Raizer, J | 1 |
| Nishikawa, R | 1 |
| Choi, JR; Jang, SJ; Kim, SH; Kim, SJ; Lee, CH; Lee, ST; Park, TS; Song, J; Suh, B | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M | 1 |
| Ikeya, T; Nitta, Y; Sakakibara, A; Tomita, Y | 1 |
| Advani, RH; Balise, R; Greenberg, PL; Hoppe, RT; Horning, SJ; Koontz, MZ; Rosenberg, SA | 1 |
| Ahmed, T; Lerner, R; Liu, D; Nelson, J; Seiter, K; Siddiqui, AD | 1 |
| Chang, MC; Chiang, MF; Hsieh, RK; Su, YW | 1 |
| Baehring, J; Ballen, KK; Berliner, N; Henson, JW; Kracher, J; Lacy, J; Noronha, V | 1 |
| Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL | 1 |
| Kageshita, T; Kuribayashi, N; Ono, T | 1 |
| Ando, K; Hayashi, S; Kimura, Y; Miyazawa, K; Mukai, K; Ohyashiki, K; Serizawa, H; Shimamoto, T; Yguchi, M | 1 |
5 review(s) available for dacarbazine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Doxorubicin; Hodgkin Disease; Humans; Leukemia, Radiation-Induced; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radiotherapy; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Vinblastine | 2017 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Temozolomide | 2016 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Glioblastoma; Humans; Leukemia, Myeloid, Acute; Lomustine; Myelodysplastic Syndromes; Neoplasms, Second Primary; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, Human, Pair 11; Dacarbazine; Fatal Outcome; Female; Gene Deletion; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Temozolomide | 2005 |
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
Topics: Aged; Breast Neoplasms; Dacarbazine; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oligodendroglioma; Temozolomide | 2006 |
2 trial(s) available for dacarbazine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2014 |
Evaluation of temozolomide in patients with myelodysplastic syndrome.
Topics: Aged; Anemia; Antineoplastic Agents, Alkylating; Cardiomyopathies; Dacarbazine; Drug Evaluation; Female; Fever; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Temozolomide; Treatment Failure | 2004 |
13 other study(ies) available for dacarbazine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Male; Melanoma; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms | 2014 |
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Time Factors | 2015 |
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Combined Modality Therapy; Dacarbazine; Female; Humans; Myelodysplastic Syndromes; Neoplasm Metastasis; Neuroblastoma; Recurrence; Temozolomide | 2008 |
Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Fatal Outcome; Humans; Male; Myelodysplastic Syndromes; Temozolomide | 2008 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Reoperation; Survival Analysis; Survivors; Temozolomide; Time Factors | 2009 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Skin; Temozolomide | 2009 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Glyoxal; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednimustine; Prednisone; Procarbazine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; Vinblastine; Vincristine | 2011 |
Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Female; Foot Diseases; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nimustine; Retrospective Studies; Vincristine | 2011 |
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; California; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Databases, Factual; Doxorubicin; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Melphalan; Methotrexate; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Vinblastine; Vincristine | 2013 |
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1995 |
Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms; Vincristine | 2000 |
Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone Marrow; CD4-CD8 Ratio; Cell Lineage; Combined Modality Therapy; Cyclosporine; Dacarbazine; DNA, Neoplasm; DNA, Viral; Doxorubicin; Endothelial Growth Factors; Fever; Fibroblast Growth Factor 2; Gene Rearrangement, B-Lymphocyte; Humans; Immunocompromised Host; Immunosuppressive Agents; Inflammation; Interleukin-6; Lymph Nodes; Lymphokines; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia; Prednisolone; Remission Induction; Splenectomy; Syndrome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vinblastine | 2001 |